On April 25, 2024, Mark J. Simon notified Portage Biotech Inc. of his decision to resign from the board of directors of the Company and all committees thereof, effective immediately. On April 26, 2024, Linda M. Kozick and Robert H. Glassman, M.D. notified the Company of their respective decisions to resign from the Board and all committees thereof, both effective immediately. On April 30, 2024, the Board appointed Jean-Christophe Renondin, M.D. and Justin Stebbing, M.D., Ph.D. as directors.

Both Dr. Renondin and Dr. Stebbing have been appointed to the Nominating Committee of the Board and the Audit Committee of the Board. Each of Dr. Renondin and Dr. Stebbing?s compensation will be consistent with the compensation provided to the Company?s non-employee directors, as described in the Company?s Annual Report on Form 20-F for the fiscal year ended March 31, 2023 filed with the Securities and Exchange Commission on July 31, 2023. The current composition of the committees of the Board is as follows: Audit Committee: Steven Mintz (Chair), Jean-Christophe Renondin and Justin Stebbing, Nominating Committee: Jean-Christophe Renondin (Chair), Gregory Bailey and Justin Stebbing, and Compensation Committee: James Mellon (Chair), Gregory Bailey and Steven Mintz.